Global Recombinant Therapeutic Antibodies and Proteins Market Professional Survey Report 2019

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Recombinant Therapeutic Antibodies and Proteins Revenue
• 1.4 Market by Type
  • 1.4.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Plasma Protein
  • 1.4.3 Fusion Proteins
  • 1.4.4 Monoclonal Antibodies
  • 1.4.5 Hormones
  • 1.4.6 Enzyme
  • 1.4.7 Coagulation Factors
  • 1.4.8 Others
• 1.5 Market by Application
  • 1.5.1 Global Recombinant Therapeutic Antibodies and Proteins Market Share by Application: 2020 VS 2026
  • 1.5.2 Oncology
  • 1.5.3 Hematology
  • 1.5.4 Immunology
  • 1.5.5 Endocrinology
  • 1.5.6 Infectious Disease
  • 1.5.7 Cardiovascular Disease
  • 1.5.8 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Perspective (2015-2026)
• 2.2 Global Recombinant Therapeutic Antibodies and Proteins Growth Trends by Regions
  • 2.2.1 Recombinant Therapeutic Antibodies and Proteins Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Recombinant Therapeutic Antibodies and Proteins Historic Market Share by Regions (2015-2020)
  • 2.2.3 Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Recombinant Therapeutic Antibodies and Proteins Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Recombinant Therapeutic Antibodies and Proteins Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Market Size
  • 3.1.1 Global Top Recombinant Therapeutic Antibodies and Proteins Players by Revenue (2015-2020)
  • 3.1.2 Global Recombinant Therapeutic Antibodies and Proteins Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Recombinant Therapeutic Antibodies and Proteins Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio
  • 3.2.1 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Recombinant Therapeutic Antibodies and Proteins Revenue in 2019
• 3.3 Recombinant Therapeutic Antibodies and Proteins Key Players Head office and Area Served
• 3.4 Key Players Recombinant Therapeutic Antibodies and Proteins Product Solution and Service
• 3.5 Date of Enter into Recombinant Therapeutic Antibodies and Proteins Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Recombinant Therapeutic Antibodies and Proteins Historic Market Size by Type (2015-2020)
• 4.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)
• 5.2 Global Recombinant Therapeutic Antibodies and Proteins Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
• 6.2 Recombinant Therapeutic Antibodies and Proteins Key Players in North America (2019-2020)
• 6.3 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
• 6.4 North America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
• 7.2 Recombinant Therapeutic Antibodies and Proteins Key Players in Europe (2019-2020)
• 7.3 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
• 7.4 Europe Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)

8 China

• 8.1 China Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
• 8.2 Recombinant Therapeutic Antibodies and Proteins Key Players in China (2019-2020)
• 8.3 China Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
• 8.4 China Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
• 9.2 Recombinant Therapeutic Antibodies and Proteins Key Players in Japan (2019-2020)
• 9.3 Japan Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
• 9.4 Japan Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
• 10.2 Recombinant Therapeutic Antibodies and Proteins Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
• 10.4 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)

11 India

• 11.1 India Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
• 11.2 Recombinant Therapeutic Antibodies and Proteins Key Players in India (2019-2020)
• 11.3 India Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
• 11.4 India Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Recombinant Therapeutic Antibodies and Proteins Market Size (2015-2020)
• 12.2 Recombinant Therapeutic Antibodies and Proteins Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Recombinant Therapeutic Antibodies and Proteins Market Size by Type (2015-2020)
• 12.4 Central & South America Recombinant Therapeutic Antibodies and Proteins Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Abbott
  • 13.1.1 Abbott Company Details
  • 13.1.2 Abbott Business Overview
  • 13.1.3 Abbott Recombinant Therapeutic Antibodies and Proteins Introduction
  • 13.1.4 Abbott Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020))
  • 13.1.5 Abbott Recent Development
• 13.2 Amgen
  • 13.2.1 Amgen Company Details
  • 13.2.2 Amgen Business Overview
  • 13.2.3 Amgen Recombinant Therapeutic Antibodies and Proteins Introduction
  • 13.2.4 Amgen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
  • 13.2.5 Amgen Recent Development
• 13.3 Biogen
  • 13.3.1 Biogen Company Details
  • 13.3.2 Biogen Business Overview
  • 13.3.3 Biogen Recombinant Therapeutic Antibodies and Proteins Introduction
  • 13.3.4 Biogen Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
  • 13.3.5 Biogen Recent Development
• 13.4 Eli Lilly
  • 13.4.1 Eli Lilly Company Details
  • 13.4.2 Eli Lilly Business Overview
  • 13.4.3 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Introduction
  • 13.4.4 Eli Lilly Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
  • 13.4.5 Eli Lilly Recent Development
• 13.5 Roche
  • 13.5.1 Roche Company Details
  • 13.5.2 Roche Business Overview
  • 13.5.3 Roche Recombinant Therapeutic Antibodies and Proteins Introduction
  • 13.5.4 Roche Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
  • 13.5.5 Roche Recent Development
• 13.6 Johnson and Johnson
  • 13.6.1 Johnson and Johnson Company Details
  • 13.6.2 Johnson and Johnson Business Overview
  • 13.6.3 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Introduction
  • 13.6.4 Johnson and Johnson Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
  • 13.6.5 Johnson and Johnson Recent Development
• 13.7 Merck
  • 13.7.1 Merck Company Details
  • 13.7.2 Merck Business Overview
  • 13.7.3 Merck Recombinant Therapeutic Antibodies and Proteins Introduction
  • 13.7.4 Merck Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
  • 13.7.5 Merck Recent Development
• 13.8 Novo Nordisk
  • 13.8.1 Novo Nordisk Company Details
  • 13.8.2 Novo Nordisk Business Overview
  • 13.8.3 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Introduction
  • 13.8.4 Novo Nordisk Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
  • 13.8.5 Novo Nordisk Recent Development
• 13.9 Pfizer
  • 13.9.1 Pfizer Company Details
  • 13.9.2 Pfizer Business Overview
  • 13.9.3 Pfizer Recombinant Therapeutic Antibodies and Proteins Introduction
  • 13.9.4 Pfizer Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
  • 13.9.5 Pfizer Recent Development
• 13.10 Sanofi
  • 13.10.1 Sanofi Company Details
  • 13.10.2 Sanofi Business Overview
  • 13.10.3 Sanofi Recombinant Therapeutic Antibodies and Proteins Introduction
  • 13.10.4 Sanofi Revenue in Recombinant Therapeutic Antibodies and Proteins Business (2015-2020)
  • 13.10.5 Sanofi Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer